Objective: The aim of this study is to review issues of legal liability in prescribing choice. Prescribing not only occurs in a medical setting, but also in a social and legal context in this era of evidence-based medicine and greater consumer awareness. Prescribers may be unaware of the legal consequences of medical decision-making and prescribing choice. This issue affects all areas of medicine and can be illustrated by antidepressant choice for major depression.
Method: A review was undertaken of liability issues that may arise in the context of prescribing, with particular reference to prescribing antidepressants. Results: There are legal precedents which illustrate prescribers' potential liability. These impose duties on the prescriber including those of care, to inform, and to respond to patients' wishes. In particular, the duty of care requires that if medicines are of equal efficacy, one should prescribe the best tolerated and least toxic medicine that is most likely to be taken at an effective dose for an adequate duration. While older and newer antidepressants are generally of equal efficacy, the newer agents have higher tolerability, lower toxicity and are less likely to be associated with treatment failure (due to sub-therapeutic dose regimens, or the patient discontinuing medication), disabling psychomotor impairment, dietary interaction or fatal overdose.
Conclusions: There needs to be compelling reasons for prescribing medicines with a greater likelihood of adverse outcomes such as the older antidepressants (e.g. tri-cyclics) rather than the newer antidepressants such as RIMAs, SSRls, SNRls and 5HT2 receptor antagonists. The higher likelihood of an adverse outcome of treatment where an older antidepressant has been prescribed raises the potential for professional negligence claims to be brought against medical practitioners who prescribe such medicines for reasons other than established medical need.
NisselleP.Is there a medical litigation crisis?Medical Journal of Australia1996; 164:178–182.
2.
Rogers v Whitaker (1992) 175 CLR 479.
3.
Hribar v Wells (1995) 64 SASR 129.
4.
Howarth & Adey (1996) 2 VR 535.
5.
O'Shea v Sullivan (1994) Aust Torts Reports 81–273.
6.
Stairmand v Baker (CA (NSW), Priestley, Clarke and Handley JJA, No. 40778/91, 7 February 1992, unreported).
7.
Putnam v Huber (SC (NSW), Studdert J, No. 12691/90, 18 February 1991, unreported).
8.
McDonell v Reed (SC (NSW), Giles J. No. 20470/94, 7 November 1994, unreported).
9.
Sturch v Willmott (SC (Qld), Thomas J, No. 1302/94, 13 April 1995, unreported).
10.
Lowns v Woods (1996) Aust Torts Reports 81–376.
11.
Albrighton v Royal Prince Alfred Hospital [1980] 2 NSWLR 542.
12.
Frost v Board of Management of Royal Perth Hospital (1995 14 SR (NSW) 141; see also Board of Management of Royal Perth Hospital v Frost (SC(WA), Malcolm CJ, Rowland and Wallwork JJ, No. 130/95, 13 June 1996 and 26 February 1997, unreported).
13.
Geissman v O'Keefe (SC (NSW), Simpson J, No. 15758/91, 25 November 1994, unreported).
14.
Jackson v Vercoe (SC (SA), King CJ, White J, Bollen J, no. 2081/86, 17 January 1992, unreported).
15.
Woods v Lowns (1995) 36 NSWLR 344.
16.
Lipovac v Hamilton Holdings Ply Limited (SC (ACT), Higgins J, No. SC 501/93, 13 September 1996 and 17 January 1997, unreported).
17.
A Policy on the quality use of medicines. Canberra: Pharmaceutical Health and the Rational Use of Medicines (PHARM) Committee, Commonwealth Department of Health, Housing and Community Services, 1992.
18.
World Health Organization.Guide to good prescribing. WHO Action Programme on Essential Drugs. Geneva: World Health Organization, 1995.
19.
DaviesBBurrowsGDumovicP.Effects on the heart of different tricyclic antidepressants. In: MendlsJ, ed. Sinequan (doxepin HCL): a monograph of recent clinical studies. Amsterdam: Excerpta Medica1975:54–58.
20.
TobisJMAronowWSCardiotoxicity of amitriptyline and doxepin. Clinical Pharmacology and Therapeutics1981; 29:359–364.
21.
VohraJBurrowsGHuntDSlomanG.The effect of toxic and therapeutic doses of tricyclic antidepressant drugs on intracardiac conduction. European Journal of Cardiology1975; 3:219–227.
22.
KristiansenESCardiac complications during treatment with imipramine (Tofranil). Acta Psychiatrica Scandinavica1961; 36:427–442.
23.
MoirDCCrooksJ.Cornwell, WB. Cardiotoxicity of amitriptyline. Lancet1972; 2:561–564.
24.
CassidySHenryJ.Fatal toxicity of antidepressant drugs in overdose. British Medical Journal1987; 295:1021–1024.
25.
RasmussenEBKristjansenP.ECG changes during amitriptyline treatment. American Journal of Psychiatry1963; 119:781–782.
26.
BarnesRJKongSMWuRWYElectrocardiographic changes in amitriptyline poisoning. British Medical Journal1968; 3:222.
27.
FreemanJWMundyGRBeattieRRRyanC.Cardiac abnormalities in poisoning with tricyclic antidepressants. British Medical Journal1969; 2:610.
28.
VeithRCRaskindMACaldwellJHBarnesRFGumbrechtGRitchieJLCardiovascular effects of tricyclic antidepressants in depressed patients with chronic heart disease. New England Journal of Medicine1982; 306:954–959.
29.
GlassmanAHBiggerJTCardiovascular effects of therapeutic doses of the tricyclic antidepressants: a review. Archives of General Psychiatry1981; 38:815–820.
30.
BiggerJTGiardinaEGVPerelJMKantorSJGlassmanAHCardiac antiarrhythmic effect of imipramine hydrochloride. New England Journal of Medicine1977; 296:206–208.
31.
BurrowsGDNormanTRWho bears the costs of antidepressants in Australia?[letter] Medical Journal of Australia1995; 162:162.
32.
TillerJWGWho bears the costs of antidepressants in Australia?[letter] Medical Journal of Australia1995; 162:163.
33.
HaskiRRGraingerD.Who bears the costs of antidepressants in Australia?[letter] Medical Journal of Australia1995; 162:164.
34.
MontgomerySAKasperS.Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. International Clinical Psychopharmacology1995; 9(Suppl. 4):33–40.
35.
AngstJStablM.Efficacy of moclobemide in different patient groups: a meta-analysis of studies. Psychopharmacology1992; 106:S109–S113.
36.
Delini-StulaAMikkelsenHAngstJ.Therapeutic efficacy of antidepressants in agitated anxious depression–a metaanalysis of moclobemide studies. Journal of Affective Disorders1995; 35:21–30.
37.
LeonardBEPharmacological differences of serotonin reuptake inhibitors and possible clinical relevance. Drugs1992; 43:3–10.
38.
AusterR.Sertraline: a new antidepressant. American Family Physician1993; 48:311–314.
39.
BuckleyNAShyteIMDawsonAHMcManusPRFergusonNWSelf-poisoning in Newcastle, 1987–1992. Medical Journal of Australia1995; 162:194–196.
40.
MyersLBDeanBSKrenzelokEPSertraline: a pediatric overdose approach [abstract]. Veterinary and Human Toxicology1994; 36:361.
41.
SpykerDACantilenaLRCardiovascular and CNS adverse events for Antidepressants Reported to the FDA [abstract]. Clinical Pharmacology and Therapeutics1995; 57:190.
42.
DooganDPToleration and safety of sertraline: experience worldwide. International Clinical Pharmacology1991; 6(Supp 2):47–56.
43.
BrownDFKerrHDSertraline overdose [case report]. Annals of Pharmacotherapy1994; 28:1307.
44.
CaracciG.Unsuccessful suicide attempt by sertraline overdose [letter]. American Journal of Psychiatry1994; 151:1.
45.
HenryJAAlexanderCASenerEKRelative mortality from overdose of antidepressants. British Medical Journal1995; 310:221–224.
46.
Klein-SchwartzWAndersonB.Analysis of sertraline only overdoses [abstract]. Veterinary and Human Toxicology1984; 36:378.
47.
BertiCWardRAByfieldRHenryJAEvaluation of sertraline overdoses reported in the United Kingdom. Presented at the European Medical Research Group Meeting (part of the European Association of Internal Medicine), London, 11 July 1994.
48.
GoldneyRDTrowseMMChiaMMSaving of SSRI overdose [letter]. Medical Journal of Australia1995; 162:668–669.
49.
MitchellPBThe new antidepressants: a guide for GPs. Modern Medicine (Australia)1994; Dec: 16–20.
50.
MitchellPBSelective serotonin reuptake inhibitors. Fantasies and controversies. Current Therapeutics1995; April:9–13.
51.
MitchellPBThe new antidepressants–are they worth the cost?Australian Prescriber1995; 18:82–84.
52.
GoldneyRDWho bears the costs of antidepressants in Australia?[letter] Medical Journal of Australia1995; 162:162.
53.
WhiteB.Who bears the costs of antidepressants in Australia?[letter] Medical Journal of Australia1995; 162:163.
54.
BlackwellBMarleyEPriceJTaylorD.Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. British Journal of Psychiatry1967; 113:349–365.
55.
TillerJWGThe new antidepressants. Australian Prescriber1995; 18:92–96.
56.
StokesPEFluoxetine: a five year review. Clinical Therapeutics1993; 15:216–243.
57.
JohnsonDAWDepression: treatment compliance in general practice. Acta Psychiatrica Scandinavica1981; 63:447–453.
58.
KerrJSFairweatherDBHindmarchI.Medicines and accidents. The Safety and Health Practitioner1992; 10:17–18.
59.
HindmarchISubhanZStokerMJEffects of zimeldine and amitriptyline on car driving and psychomotor performance. Acta Psychiatrica Scandinavica1983; 308:141–146.
60.
AshfordJJFluvoxamine and tricyclic antidepressants (TCAs): how do the TCAs compare as ‘new’ drugs with established fluvoxamine?International Clinical Psychopharmacology1995; 9(Suppl. 4):27–31.
61.
Bolam v Friern Hospital Management Committee [1957] 1 WLR 582; see also Sidaway v Governors of Bethlem Royal Hospital [1985] 1 AC 871, 880 per Lord Scarman.
62.
MitchellPBMitchellMSThe management of depression. Part 2. The place of the new antidepressants. Australian Family Physician1994; 23:1771–1781.
63.
F v R (1983) 33 SASR 189, 196 per King CJ; 207 per Bollen J.
64.
AlchinTMTranbyHWWho bears the cost of antidepressants in Australia?Medical Journal of Australia1994; 161:547–549.
65.
JonssonBBobbingtonPEWhat price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. British Journal of Psychiatry1994; 164:665–673.
66.
Wyong Shire Council v Shirt (1980) 146 CLR 40, 47–48 per Mason J.